80022119: Safety and Comorbidity of Biologic Therapeutics in Inflammatory Arthritis

The content for this online course is located at http://www.hopkins-arthritis.org/physician-corner/cme/safety-and-comorbidity-of-biologic-therapeutics-in-inflammatory-arthritis.html

COURSE DESCRIPTION

Chronic inflammatory joint diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing Spondylitis are highly destructive and disabling diseases that affect millions of individuals in the US and worldwide. Fortunately, treatment of these conditions has advanced tremendously in the last decade, largely because of the development of targeted biological therapies and a more aggressive management approach. Patients are experiencing less pain and joint damage and thus higher quality of life as a result of these treatment strategies. Exciting emerging data, at least in rheumatoid arthritis, suggest that cardiovascular risk may be reduced, and life span prolonged, as a result of more aggressive treatment. Given the complexities of treatment options available, today’s this activity will provide clinicians with cutting edge information to enable them to choose and monitor treatment strategies that achieve maximal improvement of their patients without incurring undue risk.

TARGET AUDIENCE

This activity is intended for rheumatologists.

OBJECTIVES

After viewing this activity, the participant will demonstrate the ability to:

• Identify the spectrum of therapeutic agents currently approved for the treatment of inflammatory arthritis
• Identify the systemic effects of inflammation - e.g. on hematopoieses, metabolic pathways, atherosclerosis - in patients with chronic inflammatory arthritis
• Distinguish the types of infectious risk that are enhanced by biological therapies for inflammatory arthritis
• Define the types of malignancy risk that may be enhanced by chronic inflammation itself as well as by biological therapies

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity was approved on May 15, 2010.
Released: May 15, 2010
Expires: May 14, 2013

NOTICE ABOUT OFF-LABEL USE PRESENTATIONS

The Johns Hopkins University School of Medicine/Safety and Comorbidity Considerations of Biologic Therapeutics in Inflammatory Arthritis may include presentations on drugs or devices, or use of drugs or devices, that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.

COPYRIGHT INFORMATION

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.

TO OBTAIN CME CREDIT

To obtain CME Credits for this activity. You must visit the Johns Hopkins Arthritis Center website and view the videos at http://www.hopkins-arthritis.org/physician-corner/cme/safety-and-comorbidity-of-biologic-therapeutics-in-inflammatory-arthritis.html, then register online at this site (please use register button at the top of this page). After you have registered and paid the $35 registration fee for this activity please follow these steps.

1. Links for the post tests and evaluations will appear in your Learning Schedule.

2. To access your Learning Schedule, login and go to pending post tests/evaluations

3. Click checkbox next to Display Available Session Exams, Evaluations and Attestations a. Select the appropriate post test, evaluation or attestation you wish to complete. B. Please note - you will need to complete the post test, evaluation and attestation for each session to receive your CME certificate.
Release Date: May 15, 2010
Expiration Date: May 14, 2013

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.